 Patients are followed at week 18 after catheter placement and then every 8 weeks thereafter until death, disease progression, or completion of six months phase I or 12 months phase II of follow-up after the end of IL13-PE38QQR infusion. Phase II patients who complete one year of follow-up without disease progression are followed every 12 weeks thereafter until death. 